0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
The Cutting Edge: Challenges in Medical and Surgical Therapies |

Efficacy of Intravenous Cidofovir in the Treatment of Giant Molluscum Contagiosum in a Patient With Human Immunodeficiency Virus

Corinne Erickson, MD; Marcia Driscoll, MD; Anthony Gaspari, MD
Arch Dermatol. 2011;147(6):652-654. doi:10.1001/archdermatol.2011.20.
Text Size: A A A
Published online

Extract

Molluscum contagiosum virus (MCV) is a DNA virus in the Poxviridae family that may cause extensive and voluminous lesions often resistant to topical therapies in patients with AIDS and other immunocompromised patients. We present a case of eruptive giant molluscum that caused remarkable deformity in a patient with AIDS. Intravenous (IV) cidofovir was used as therapy, resulting in dramatic improvement.

REFERENCES
Pereira  BFernandes  CNachiambo  ECatarino  MCRodrigues  ACardoso  J Exuberant molluscum contagiosum as a manifestation of the immune reconstitution inflammatory syndrome. Dermatol Online J 2007;13 (2) 6
PubMed
French  MA HIV/AIDS: immune reconstitution inflammatory syndrome: a reappraisal. Clin Infect Dis 2009;48 (1) 101- 107
PubMed Link to Article[[XSLOpenURL/10.1086/596722]]
Cronin  TA  JrResnik  BIElgart  GKerdel  FA Recalcitrant giant molluscum contagiosum in a patient with AIDS. J Am Acad Dermatol 1996;35 (2, pt 1) 266- 267
PubMed Link to Article[[XSLOpenURL/10.1016/S0190-9622(96)90348-5]]
Briand  SMilpied  BNavas  DThomare  PStalder  JF 1% topical cidofovir used as last alternative to treat viral infections. J Eur Acad Dermatol Venereol 2008;22 (2) 249- 250
PubMed
Davies  EGThrasher  ALacey  KHarper  J Topical cidofovir for severe molluscum contagiosum. Lancet 1999;353 (9169) 2042
PubMed Link to Article[[XSLOpenURL/10.1016/S0140-6736(99)01782-1]]
Meadows  KPTyring  SKPavia  ATRallis  TM Resolution of recalcitrant molluscum contagiosum virus lesions in human immunodeficiency virus–infected patients treated with cidofovir. Arch Dermatol 1997;133 (8) 987- 990
PubMed Link to Article[[XSLOpenURL/10.1001/archderm.1997.03890440061010]]
Toro  JRWood  LVPatel  NKTurner  ML Topical cidofovir: a novel treatment for recalcitrant molluscum contagiosum in children infected with human immunodeficiency virus 1. Arch Dermatol 2000;136 (8) 983- 985
PubMed
Zabawski  EJ  Jr A review of topical and intralesional cidofovir. Dermatol Online J 2000;6 (1) 3
PubMed
Zabawski  EJ  JrCockerell  CJ Topical and intralesional cidofovir: a review of pharmacology and therapeutic effects. J Am Acad Dermatol 1998;39 (5, pt 1) 741- 745
PubMed Link to Article[[XSLOpenURL/10.1016/S0190-9622(98)70046-5]]
Ibarra  VBlanco  JROteo  JARosel  L Efficacy of cidofovir in the treatment of recalcitrant molluscum contagiosum in an AIDS patient. Acta Derm Venereol 2000;80 (4) 315- 316
PubMed Link to Article[[XSLOpenURL/10.1080/000155500750012333]]
Lalezari  JPStagg  RJKuppermann  BD  et al.  Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS: a randomized, controlled trial. Ann Intern Med 1997;126 (4) 257- 263
PubMed Link to Article[[XSLOpenURL/10.7326/0003-4819-126-4-199702150-00001]]
Centers for Disease Control and Prevention (CDC), Progressive vaccinia in a military smallpox vaccinee—United States, 2009. MMWR Morb Mortal Wkly Rep 2009;58 (19) 532- 536
PubMed
Ciesla  SLTrahan  JWan  WB  et al.  Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney. Antiviral Res 2003;59 (3) 163- 171
PubMed Link to Article[[XSLOpenURL/10.1016/S0166-3542(03)00110-4]]
Parker  STouchette  EOberle  C  et al.  Efficacy of therapeutic intervention with an oral ether-lipid analogue of cidofovir (CMX001) in a lethal mousepox model. Antiviral Res 2008;77 (1) 39- 49
PubMed Link to Article[[XSLOpenURL/10.1016/j.antiviral.2007.08.003]]
Trost  LCTrippin  TKAnderson  MTPainter  WPChimerix Inc,Compromised renal function does not affect the pharmacokinetics of CMX001 in patients with severe double-stranded DNA virus infections.http://www.chimerix-inc.com/images/uploads/2010%20ICAAC%20Poster.pdf13 September2010;
Figures in this Article

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview

Figures

Place holder to copy figure label and caption
Figure.

Patient before (A), during (B), and after (C) intravenous cidofovir treatment course.

Graphic Jump Location

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

617 Views
10 Citations
×

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Jobs
JAMAevidence.com

Care at the Close of Life: Evidence and Experience
Overcoming the False Dichotomy of Curative vs Palliative Care for Late-Stage HIV/AIDS: "Let Me Live the Way I Want to Live, Until I Can't"

The Rational Clinical Examination: Evidence-Based Clinical Diagnosis
Evidence to Support the Update

brightcove.createExperiences();